PHARMAC responds on Herceptin assumptions and decisions [1]

New Zealand Medical Journal

Volumn 120, Issue 1260, 2007, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT THERAPY; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; EARLY CANCER; EVIDENCE BASED MEDICINE; FINANCIAL MANAGEMENT; HEALTH CARE COST; HUMAN; LETTER; MEDICAL DECISION MAKING; MEDICAL ETHICS; METHODOLOGY; MONOTHERAPY; OVERALL SURVIVAL; PEER REVIEW; PROSPECTIVE PRICING; SAMPLE SIZE;

EID: 36148971972     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Letter

References (20)

1. Isaacs RJ, Frampton CM, Kuper-Hummel MJJ. PHARMAC's funding of 9 weeks Herceptin: Many assumptions in a high-risk decision. N Z Med J. 2007;120(1259). http://www.nzma.org.nz/journal/120-1259/2676/
2. Metcalfe S, Evans J, Priest G. PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-positive early breast cancer. N Z Med J. 2007 15 June;120(1256). http://www.nzma.ora.nz/journal/120-1256/ 2593
3. http://www.pharmac.govt.nz/herceptin.asp
4. Wells S. Summary of GATE critical appraisals of trastuzumab trials. EPIQ, University of Auckland, May 2007. http://www.health.auckland.ac.nz/population-health/ epidemiology-biostats/epiq/critical_appraisal_library/Herceptin
5. Perez EA. Further Analysis of NCCTG-N9831. Slide presentation ASCO annual meeting 2005. http://www.asco.org/ac/ 1,1003,_12-002511-00_18-0034-00_19-005815-00_21-001,00.asp
6. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354(8):809-20. http://content.nejm.org/cgi/content/full/354/8/809
7. Smith I, Procter M, Gelber RD, et al. 2 year follow up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet. 2007;369:29-36. http://www.thelancet.com/ journals/lancet/article[PIIS0140673607600282/fulltext
8. PHARMAC. TAR 75 Trastuzumab (Herceptin) in HER-2 positive early breast cancer with 9 week regimen CUA. Released May 2007. http://www.pharmac.govt.nz/pdf/030307c.pdf
9. Moodie P, McNee W, Metcalfe S. PHARMAC welcomes debate. N Z Med J. 2005;118(1218). http://www.nzma.org.nz/journal/118-1218/1572/
10. PHARMAC decision criteria at http://www.pharmac.govt.nz/ pharmaceutical_schedule_update.asp
11. Schulz KF. Assessing allocation concealment and blinding in randomised controlled trials. Why bother? Evidence Based Medicine. 2000;5:36-37.
12. Hind D, Pilgrim H, Ward S. Questions about adjuvant trastuzumab still remain. Lancet. 2007; 369:3-5. http://www.thelancet.com/journals/ lancet/article/PIIS014067360760004X/fulltext
13. Roche media release 3 May 2006. Herceptin approved in Europe for use in combination with an aromatase inhibitor for the treatment of patients with HER2 and hormone receptor co-positive metastatic breast cancer. http://www.roche.com/med-cor-2007-05-03
14. Romond, EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER-2 positive breast cancer. N Engl J Med 2005;353(16):1659-1672. http://content.nejm.org/cgi/content/full/353/ 16/1673
15. Coombes R. Cancer drugs: Swallowing big pharma's line? BMJ 2007;334:1034-5. http://www.bmj.com/cgi/content/full/334/7602/1034
16. Boseley S. Concern over cancer group's link to drug firm. The Guardian, 18 October 2006. http://society.guardian.co.uk/health/story/ 0,,1924747,00.html
17. Day M. Experts dispute claims of poor cancer survival in UK. BMJ 2007;334:1021-a. http://www.bmj.com/cgi/content/full/334/ 7602/1021-a
18. Berrino F. The EUROCARE Study: Strengths, limitations and perspectives of population-based, comparative survival studies. Ann Oncol. 2003;14 Suppl 5:v9-13. http://annonc.oxfordjournals.org/cgi/reprint/14/ suppl_5/v9
19. Madsen F, Frolund L, Nørskov B. The Eurocare 2 study re-evaluated: Ranking of countries according to survival with cancer may be flawed. BMJ website 12 June 2007. http://www.bmj.com/cgi/eletters/334/7602/ 1021-a Rapid response to Day M. Experts dispute claims of poor cancer survival in UK. BMJ 2007;334:1021-a. http://www.bmj.com/cgi/content/ full/334/7602/1021-a
20. Research behind new Europe-wide cancer campaign 'all wrong', 19 October 2006. http://www.lshtm.ac.uk/news/2006/cancerunited.html